Zentalis Pharmaceuticals (NASDAQ:ZNTL) Research Coverage Started at Leerink Partners

Leerink Partners initiated coverage on shares of Zentalis Pharmaceuticals (NASDAQ:ZNTL) in a report released on Monday morning, MarketBeat reports. The firm issued an outperform rating and a $8.00 price target on the stock.

ZNTL has been the subject of several other research reports. Weiss Ratings reissued a “sell (d-)” rating on shares of Zentalis Pharmaceuticals in a report on Friday, October 2nd. Mizuho initiated coverage on shares of Zentalis Pharmaceuticals in a report on Friday, July 17th. They set an “outperform” rating and a $8.00 target price on the stock. Wells Fargo & Company assumed coverage on shares of Zentalis Pharmaceuticals in a research report on Wednesday, September 30th. They set an “equal weight” rating and a $5.00 price target on the stock. Wall Street Zen cut shares of Zentalis Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research note on Saturday, August 8th. Finally, William Blair initiated coverage on shares of Zentalis Pharmaceuticals in a research report on Wednesday, September 16th. They issued an “outperform” rating for the company. Six analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $7.50.

Zentalis Pharmaceuticals Price Performance

Shares of NASDAQ ZNTL opened at $2.55 on Monday. The business has a 50-day moving average of $3.63 and a 200-day moving average of $3.87. The stock has a market capitalization of $182.76 million, a price-to-earnings ratio of -1.31 and a beta of 1.93. Zentalis Pharmaceuticals has a fifty-two week low of $1.21 and a fifty-two week high of $6.95.

Zentalis Pharmaceuticals (NASDAQ:ZNTL) last released its earnings results on Thursday, August 6th. The company reported ($0.59) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.49) by ($0.10). On average, sell-side analysts expect that Zentalis Pharmaceuticals will post -2.11 EPS for the current year.

Insider Activity at Zentalis Pharmaceuticals

In other Zentalis Pharmaceuticals news, major shareholder Group Walters bought 4,335,000 shares of the firm’s stock in a transaction that occurred on Friday, August 14th. The shares were acquired at an average cost of $3.50 per share, with a total value of $15,172,500.00. Following the acquisition, the insider owned 17,844,973 shares of the company’s stock, valued at $62,457,405.50. The trade was a 32.09% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Corporate insiders own 3.80% of the company’s stock.

Institutional Investors Weigh In On Zentalis Pharmaceuticals

Large investors have recently added to or reduced their stakes in the business. 5AM Venture Management LLC bought a new position in Zentalis Pharmaceuticals during the second quarter worth $19,147,378. BlackRock Inc. acquired a new stake in shares of Zentalis Pharmaceuticals during the 2nd quarter worth about $18,205,000. Bank of America Corp DE bought a new stake in shares of Zentalis Pharmaceuticals during the 2nd quarter worth about $5,406,000. Primecap Management Co. CA acquired a new position in Zentalis Pharmaceuticals in the 2nd quarter valued at about $4,643,000. Finally, Connor Clark & Lunn Investment Management Ltd. acquired a new position in Zentalis Pharmaceuticals in the 2nd quarter valued at about $3,676,000.

Zentalis Pharmaceuticals Company Profile

Zentalis Pharmaceuticals, Inc (NASDAQ: ZNTL) is a clinical-stage biopharmaceutical company focused on discovering and developing small-molecule medicines for the treatment of cancer. The company’s research programs are designed to target biological pathways involved in tumor growth, survival and resistance to existing therapies.

Zentalis’ lead investigational product is azenosertib, also known as ZN-c3, an oral WEE1 inhibitor being evaluated in clinical trials for several advanced cancers.